YOLFTbeta
Bioleaders Corporation

Bioleaders Corporation

142760 · KQ · Healthcare / Biotechnology

117.00KRW+27.00 (+30.00%)

Price History

Full chart

Market Stats

Previous Close90.00
Open100.00
Day Range97.00 – 117.00
52-Week Range463.00 – 3,788.00
Volume7.19M
Market Cap10.10B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.49
50-Day Avg641.70
200-Day Avg1,576.59

About

MOA Life Plus Co. Ltd. engages in the medicine and consumer business in South Korea. It offers P53, a target anti-cancer drug. The company's pipeline products include BLS-H01, which is in phase 3 clinical trial for the treatment of cervical cancer; BLC-H03, a vaccine adjuvant that is in preclinical stage; BLS-M07 that has completed phase 2b clinical trial for the treatment of cervical cancer; and BLS-M22 that has completed phase 1 clinical trial for the treatment of Duchenne muscular dystrophy. It also provides health functional food and raw materials, and cosmetics. The company was formerly known as Bioleaders Corporation and changed its name to MOA Life Plus Co. Ltd. in March 2024. MOA Life Plus Co. Ltd. was founded in 1999 and is headquartered in Yongin-Si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOSangJin Han
  • Employees42
  • HeadquartersA-7, 767, Sinsu-ro, Yongin-Si, South Korea, 16827, Korea
  • Websitehttps://www.moalifeplus.com

Leadership

  • SangJin HanCEO & Director
  • Mr. Hyun-Jae SungChief Financial Officer and Senior Managing Director · b. 1966
  • Mr. Chul-Joong KimChief Technology Officer · b. 1956
  • Kyung-Soo Hahm Ph.D.Head of R&D Center

Financials

Income Statement

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.48B2.50B7.61B86.07B72.88B80.45B101.17B100.41B18.25B15.63B11.22B
Growth (%)-+69.18%+204.19%+1031.41%-15.33%+10.40%+25.75%-0.75%-81.83%-14.34%-28.24%
Cost of Revenue1.04B1.73B6.71B56.69B48.51B57.80B75.44B76.15B12.66B11.04B9.36B
Gross Profit439.32M775.15M896.76M29.38B24.37B22.65B25.73B24.26B5.58B4.59B1.85B
Gross Margin29.72%31.00%11.79%34.13%33.44%28.16%25.43%24.16%30.59%29.36%16.52%
Operating Expense6.20B6.78B8.39B43.38B65.21B58.50B64.26B53.07B10.58B12.91B8.38B
Operating Income-5.76B-6.00B-7.50B-14.01B-40.84B-35.84B-38.53B-28.81B-4.99B-8.32B-6.53B
Operating Margin-389.77%-240.00%-98.54%-16.27%-56.04%-44.55%-38.09%-28.69%-27.37%-53.26%-58.23%
EBITDA--------4.32B1.83B-3.35B-9.53B
EBITDA Margin--------4.30%10.03%-21.44%-84.93%
Net Income-18.64B-5.90B-6.65B-17.23B-28.05B-21.14B-19.77B-23.14B8.01B-6.99B-13.05B
Net Income Margin-1260.95%-235.76%-87.38%-20.02%-38.48%-26.27%-19.54%-23.04%43.90%-44.75%-116.36%
R&D-2.82B2.74B2.55B-3.42B4.48B4.01B1.50B579.16M798.98M
R&D as % of Total Revenue-112.75%36.00%2.97%-4.25%4.43%3.99%8.23%3.71%7.12%
Interest Expense000006.68B5.68B4.65B1.77B2.32B1.90B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%8.30%5.62%4.63%9.72%14.83%16.97%

Balance Sheet

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets9.54B21.61B37.58B153.29B148.11B190.69B188.85B148.42B49.07B62.25B42.61B
Total Liabilities3.99B4.15B2.41B129.79B124.30B160.09B143.74B126.73B13.28B24.94B12.04B
Total Equity5.55B17.46B35.17B23.50B23.82B30.60B45.11B21.69B32.99B37.31B30.57B
Cash2.46B5.39B13.84B35.38B39.49B38.25B59.13B12.15B18.94B2.21B8.13B
Total Debt----23.80B38.96B-----
Net Debt----24.77B33.28B-39.61B-11.73B-

Cash Flow

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-4.83B-7.70B-8.53B-8.77B-2.20B-5.43B-5.04B-20.60B6.18B-501.75M-5.97B
Investing Cash Flow-2.47B-6.18B-7.13B-15.16B-16.10B-40.25B-1.27B-20.66B30.55B-34.49B-
Financing Cash Flow3.41B16.81B24.14B47.94B23.59B40.62B26.65B-6.14B-29.94B17.66B-
Capital Expenditure374.37M1.44B2.59B4.06B23.50B17.78B1.77B1.72B378.81M1.05B213.22M
Free Cash Flow------23.35B-7.23B-22.40B5.80B-1.56B-6.18B
FCF to OCF-----430.43%143.58%108.74%93.87%310.00%103.57%

Earnings

Report DateSep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018May 15, 2019Aug 14, 2019Nov 14, 2019Feb 27, 2020May 15, 2020Aug 14, 2020Nov 13, 2020Feb 26, 2021May 17, 2021Aug 17, 2021Nov 12, 2021Mar 23, 2022May 13, 2022Aug 4, 2022Nov 11, 2022Mar 23, 2023May 12, 2023Aug 14, 2023Nov 9, 2023May 14, 2024Aug 14, 2024Nov 12, 2024Feb 27, 2025May 15, 2025Aug 12, 2025Nov 12, 2025Dec 31, 2025May 13, 2026Jun 30, 2026
EPS Estimate---------------------------------------
EPS Actual-290.66-174.75-284.30-169.87-228.90-212.15-297.05-182.33-273.19-1121.25-172.40-440.35-186.49-685.29-149.12-103.31-324.00-415.44-130.78-186.67-80.87-483.23-105.32-217.78-123.33-344.63-28.5423.72-90.27-106.2425.00-43.78-95.21-36.31-186.02-18.17-197.91-27.16-375.02
Surprise---------------------------------------
Timing----------Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market---Pre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-market-Pre-market-

Key Statistics & Ratios

Market Cap10.10B
Enterprise Value14.98B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.97
Price / Book0.41
Revenue (TTM)10.46B
Gross Profit (TTM)2.00B
EBITDA-10.34B
Profit Margin-131.91%
Operating Margin-207.90%
Return on Equity-48.82%
Return on Assets-17.41%
Shares Outstanding21.08M
Shares Float17.31M
Beta0.49
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Aug 31, 20261:2
  • Sep 28, 2020594:533